+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
LALPATHLAB

Dr. Lal Pathlabs Share Price

₹1,877.30 -39 (-2.04%)
New 52W High in past week

17 Aug, 2026 3:54 PM (IST)

Dr. Lal Pathlabs live price: ₹1,877.30. It opened at ₹1,931 vs previous close ₹1,916; intraday high/low: ₹1,931/₹1,870. The 50 & 200 DMA stand at ₹1,766.10/₹1,587.10.

Dr. Lal Pathlabs Performance

  • Today's Low
  • ₹1,870
  • Today's High
  • ₹1,931
  • 52 Week Low
  • ₹1,273
  • 52 Week High
  • ₹1,989
  • Open Price₹1,931
  • Previous Close₹1,916
  • Volume147,160
  • 50 DMA₹1,766.10
  • 100 DMA₹1,668.00
  • 200 DMA₹1,587.10

Dr. Lal Pathlabs Chart

Investment Returns

  • Over 1 Month + 8.35%
  • Over 3 Month + 17.12%
  • Over 6 Month + 32.13%
  • Over 1 Year + 12.15%

Smart Investing Starts Here Start SIP with Dr. Lal Pathlabs for Steady Growth!

Invest Now

Dr. Lal Pathlabs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 58.1
  • PEG Ratio
  • 10.4
  • Market Cap Cr
  • 31,510
  • P/B Ratio
  • 12.6
  • Average True Range
  • 57
  • EPS
  • 32.3
  • Dividend Yield
  • 0.9
  • MACD Signal
  • 59.4
  • RSI
  • 56
  • MFI
  • 75

Latest Stock News Updates

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Attached

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Attached

Dr Lal Path jumps 8% to 52-week high on Q1 beat; up to 25% upside on cards

Dr Lal PathLabs' share price jumped 8 per cent to a fresh 52-week high of 1,893.65 on the BSE today. The company has posted a better-than-expected Q1 show, prompting analysts to raise target prices.

Dr. Lal Pathlabs Financials

Dr. Lal Pathlabs Technicals

EMA & SMA

Current Price
₹1,877.30
-39 (-2.04%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹1,869.90
  • 50 Day
  • ₹1,766.10
  • 100 Day
  • ₹1,668.00
  • 200 Day
  • ₹1,587.10

Resistance and Support

1892.8 Pivot Speed
  • R3 1,976.40
  • R2 1,953.70
  • R1 1,915.50
  • S1 1,854.60
  • S2 1,831.90
  • S3 1,793.70

Dr. Lal Pathlabs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-24 Quarterly Results
2026-04-30 Audited Results & Final Dividend
2026-01-30 Quarterly Results & Interim Dividend To consider other business matters.
2025-10-31 Qtr Results, Int.Dividend & Bonus issue
2025-07-31 Quarterly Results, Dividend & Others To consider other business matters.
Date Purpose Remarks
2026-07-30 INTERIM Rs.5.00 per share(50%)Interim Dividend
2026-06-26 FINAL Rs.4.00 per share(40%)Final Dividend
2026-02-05 INTERIM Rs.3.50 per share(35%)Third Interim Dividend
2025-11-07 INTERIM Rs.7.00 per share(70%)Second Interim Dividend
2025-08-06 INTERIM Rs.6.00 per share(60%)Interim Dividend
View Dr. Lal Pathlabs Dividend History Arrow
Date Purpose Remarks
2025-12-19 Bonus Bonus issue of equity shares in the ratio of 1:1 of Rs. 10/-.

Dr. Lal Pathlabs Shareholding Pattern

53.19%
18.79%
17.35%
7.48%
2.81%

About Dr. Lal Pathlabs

Dr. Lal PathLabs engaged in the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, View More
  • NSE Symbol
  • LALPATHLAB
  • BSE Symbol
  • 539524
  • ISIN
  • INE600L01024

Similar Stocks to Dr. Lal Pathlabs

Dr. Lal Pathlabs FAQs

Dr. Lal Pathlabs share price is ₹1,877 As on 17 August, 2026 | 18:21

The Market Cap of Dr. Lal Pathlabs is ₹31510.3 Cr As on 17 August, 2026 | 18:21

The P/E ratio of Dr. Lal Pathlabs is 58.1 As on 17 August, 2026 | 18:21

The PB ratio of Dr. Lal Pathlabs is 12.6 As on 17 August, 2026 | 18:21

The 52 week High & Low of Dr. Lal Pathlabs is ₹1988.9/₹1272.6 respectively As on 17 August, 2026 | 18:21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23